David Goldberg, MD
Gastroenterology · Miami, FLNPI 1891987806
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,000 of the $7,762 with a category attached, or 77.3%. Pfizer accounts for 61.2% of it on its own, with 2 other manufacturers making up the rest.
Across 4 payments — averaging $1940.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- Fidia Pharma USA Inc.$3K
- Boston Scientific$12
Across 8 payments — averaging $106,237 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$664K
- Merck$171K
- Gilead$15K
What the payments were for
- Consulting fees$1,75023%
- Speaking & faculty fees$6,00077%
- Food & beverage$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 2 | $4,750 |
| Fidia Pharma USA Inc. | 1 | $3,000 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HYALO4CARE$3,000
- XELJANZ$1,750
How this compares
$7,762 in reported general payments places this provider in the 75th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Entecavir | 16 | $8,025 |
| Ursodiol | 11 | $1,536 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 34 | $465 |
| Carvedilol | 17 | $92 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Miami
- Lukasz KwapiszMiami$1.2M
- Joanna LopezMiami$670K
- Jerry MartelMiami$511K
- Andres GelrudMiami$208K
- Maria HernandezMiami$197K
- George SanchezMiami$117K
- Jodie BarkinMiami$101K
- Javier ParraMiami$68K
- Samuel GidayOrlando$2M
- Jennifer Seminerio-DiehlOrlando$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.